In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections-Reference-Cited by-同舟云学术

In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections

Published:2021-03 Issue:3 Volume:57 Page:106291
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Beredaki Maria-Ioanna,Arendrup Maiken Cavling,Mouton Johan W.,Meletiadis Joseph^ORCID

Funder

European Society of Clinical Microbiology and Infectious Diseases

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference34 articles.

1. Invasive candidiasis;Pappas;Nat Rev Dis Primers,2018

2. The changing epidemiology of healthcare-associated candidemia over three decades;Diekema;Diagn Microbiol Infect Dis,2012

3. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemias;Orasch;Clin Microbiol Infect,2014

4. Candidaemia in Sweden: a nationwide prospective observational survey;Ericsson;Clin Microbiol Infect,2013

5. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010);Lortholary;Intensive Care Med,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approaches for posaconazole therapeutic drug monitoring and their clinical benefits;European Journal of Clinical Pharmacology;2024-09-09

2. Comparative pharmacodynamics and dose optimization of liposomal amphotericin B against Candida species in an in vitro pharmacokinetic/pharmacodynamic model;Antimicrobial Agents and Chemotherapy;2024-08-07

3. Production of new ent-hardwickiic acid derivatives by microbial transformation and their antifungal activity;Fitoterapia;2024-03

4. Defining Optimal Doses of Liposomal Amphotericin B Against Candida auris: Data From an In Vitro Pharmacokinetic/Pharmacodynamic Model;The Journal of Infectious Diseases;2023-12-18

5. Nascent Nanoformulations as an Insight into the Limitations of the Conventional Systemic Antifungal Therapies;Current Drug Targets;2023-02